Publications by authors named "F Bisbal"
Left Atrial Structure and Function Following Ethanol Infusion into Vein of Marshall (MR-SHALL Study).
J Cardiovasc Electrophysiol
January 2025
Background: Ethanol infusion into the vein of Marshall (EI-VOM) is an adjunctive therapy to pulmonary vein isolation (PVI), which improves the efficacy of persistent atrial fibrillation (AF) ablation procedures. It is unknown how EI-VOM scar formation impacts left atrium (LA) structure and function.
Objective: To characterize scar formation after EI-VOM, and its impact on LA function, by cardiac magnetic resonance (CMR).
Article Synopsis
- - A randomized trial showed that adding delayed enhancement MRI-guided fibrosis ablation to pulmonary vein isolation (PVI) for treating atrial fibrillation (AF) didn’t improve outcomes, with similar recurrence rates between the two methods.
- - The study analyzed how effectively lesions delivered during ablation covered fibrotic areas, finding that a much higher percentage of targeted fibrosis was successfully ablated using MRI guidance compared to PVI alone.
- - While overall scar coverage didn’t significantly reduce AF recurrence, lower recurrence rates were noted in patients with less baseline fibrosis when fibrosis-targeted ablation was used, indicating variability in treatment effectiveness.
Article Synopsis
- - Sacubitril/valsartan (Sac/Val) shows better outcomes than β-blockers in reducing heart failure risks and improving myocardial scar remodeling after a myocardial infarction (MI) in pigs.
- - In a study with 22 pigs post-MI, those treated with β-blocker plus Sac/Val exhibited significant reductions in inflammatory markers, scar mass, and specific types of collagen in the heart.
- - The combination treatment also led to lowered risk of ventricular tachycardia, indicating a potential therapeutic benefit for heart health after MI.
Article Synopsis
- The PERISCOPE Phase I clinical trial assessed the safety of PeriCord, a tissue graft made from decellularised pericardial matrix and umbilical cord mesenchymal cells, in patients undergoing surgical revascularization after non-acute myocardial infarction.
- In the trial, seven patients received PeriCord and demonstrated no adverse effects during the one-year follow-up, although there were no significant changes in overall quality of life or cardiac function compared to controls.
- The study highlighted PeriCord's immunomodulatory effects, specifically in influencing the behavior of circulating monocytes towards a repair-promoting state, indicating potential for further exploration in treating inflammation-related conditions.
Aims: The aim of our study was to analyse the response to short-coupled atrial extrastimuli to identify areas of hidden slow conduction (HSC) and their relationship with the atrial fibrillation (AF) phenotype.
Methods And Results: Twenty consecutive patients with paroxysmal AF and persistent AF (10:10) underwent the first pulmonary vein isolation procedure. Triple short-coupled extrastimuli were delivered in sinus rhythm (SR), and the evoked response was analysed: sites exhibiting double or highly fragmented electrograms (EGM) were defined as positive for HSC (HSC+).